Investors

News Releases

Date Title  
Toggle Summary POZEN Announces Effectiveness Of Aralez Registration Statement On Form S-4 And Provides Update On Key Milestones For 2016
- POZEN schedules stockholder meeting for February 2 , 2016-  -Plan to re-file YOSPRALA™ New Drug Application early in the second quarter; Approval and launch targeted in fourth quarter-  CHAPEL HILL, N.C. , Dec. 28, 2015 /PRNewswire/ --   POZEN Inc.
Toggle Summary RETRANSMISSION: Tribute Schedules Special Shareholder Meeting for February 1, 2016
MILTON, ONTARIO -- (Marketwired) -- 12/29/15 -- Tribute Pharmaceuticals Canada    Inc. (TSX VENTURE:TRX) (OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty    pharmaceutical company with a primary focus on the acquisition, licensing,    development and promotion

Copyright West LLC. Minimum 15 minutes delayed.